Skip to main content

Dantrolene Dosage

Medically reviewed by Drugs.com. Last updated on May 1, 2024.

Applies to the following strengths: 25 mg; 50 mg; 100 mg; 20 mg; 250 mg

Usual Adult Dose for Malignant Hyperthermia

TREATMENT of Malignant Hyperthermia (MH): 1 mg/kg IV push

Maximum Cumulative dose: 10 mg/kg

If Physiologic and Metabolic Abnormalities of MH Reappear: Repeat dosing starting with 1 mg/kg IV

Institute the following supportive measures with dantrolene therapy:

Comments:

PREVENTION of Malignant Hyperthermia (MH):
Preoperatively:

Postoperatively:
Duration of Therapy: 1 to 3 days

Comments:

Uses:

Usual Adult Dose for Chronic Spasticity

Dosage should be titrated and individualized for maximum effect; the lowest dose compatible with optimal response is recommended: therapy should be stopped if benefits are not evident within 45 days

Initial dose: 25 mg orally once a day for 7 days, then
25 mg orally 3 times a day for 7 days
50 mg orally 3 times a day for 7 days
100 mg orally 3 times a day
Maximum dose: 100 mg orally 4 times a day

Comments:


Use: For use controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis.

The decision to continue therapy on a long-term basis is justified if this drug produces a significant reduction in painful and/or disabling spasticity such as clonus, permits a significant reduction in the intensity and/or degree of nursing care required, or eliminates annoying manifestations of spasticity considered important by the patient.

Usual Pediatric Dose for Malignant Hyperthermia

TREATMENT of Malignant Hyperthermia (MH): 1 mg/kg IV push

Maximum Cumulative dose: 10 mg/kg

If Physiologic and Metabolic Abnormalities of MH Reappear: Repeat dosing starting with 1 mg/kg IV

Institute the following supportive measures with dantrolene therapy:

Comments:

PREVENTION of Malignant Hyperthermia (MH):
Preoperatively:

Postoperatively:
Duration of Therapy: 1 to 3 days

Comments:

Uses:

Usual Pediatric Dose for Chronic Spasticity

5 years or older:

Dosage should be titrated and individualized for maximum effect; the lowest dose compatible with optimal response is recommended: therapy should be stopped if benefits are not evident within 45 days

Initial dose: 0.5 mg/kg orally once a day for 7 days, then
0.5 mg/kg orally 3 times a day for 7 days
1 mg/kg orally 3 times a day for 7 days
2 mg/kg orally 3 times a day
Maximum dose: 100 mg orally 4 times a day

Comments:


Use: For use controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis.

The decision to continue therapy on a long-term basis is justified if this drug produces a significant reduction in painful and/or disabling spasticity such as clonus, permits a significant reduction in the intensity and/or degree of nursing care required, or eliminates annoying manifestations of spasticity considered important by the patient.

Renal Dose Adjustments

No adjustments recommended

Liver Dose Adjustments

Chronic Spasticity:

Dose Adjustments

Elderly: Dose selection should be cautious; use the lowest dose compatible with optimal response

Precautions

US BOXED WARNINGS: HEPATOTOXICITY (Capsules)


CONTRAINDICATIONS: Oral Therapy:

CONTRAINDICATIONS: Intravenous Therapy

Safety and efficacy of the oral capsules have not been established in patients younger than 5 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
IV administration; Use care to prevent extravasation into surrounding tissues

Storage requirements:


Reconstitution/preparation techniques:

General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.